Free Trial
→ Nobody Understands Why Trump Is Invading Iran (here’s the answer) (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:NRXP

NRx Pharmaceuticals Q1 2026 Earnings Report

NRx Pharmaceuticals logo
$3.04 +0.04 (+1.33%)
Closing price 04:00 PM Eastern
Extended Trading
$3.08 +0.04 (+1.28%)
As of 05:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

NRx Pharmaceuticals EPS Results

Actual EPS
N/A
Consensus EPS
-$0.01
Beat/Miss
N/A
One Year Ago EPS
N/A

NRx Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
$25.57 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

NRx Pharmaceuticals Announcement Details

Quarter
Q1 2026
Date
5/21/2026
Time
Before Market Opens
Conference Call Date
Thursday, May 14, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

NRx Pharmaceuticals Earnings Headlines

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine
May 5 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3287507/0/en/nrx-pharmaceuticals-nasdaq-nrxp-announces-initiation-of-commercial-manufacturing-for-preservative-free-ketamine.html
NRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program
April 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/22/3278820/0/en/nrx-pharmaceuticals-reports-positive-fda-office-of-generic-drugs-feedback-on-preservative-free-ketamine-program.html
Elon Musk’s $1 Quadrillion AI IPO
$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today.tc pixel
May 5 at 1:00 AM  |  Brownstone Research (Ad)
NRx Pharmaceuticals (NASDAQ: NRXP) Supports Executive Order To Accelerate Psychedelic Drug Development
April 20, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Investor%20Brand%20Network/1405663/nrx-pharmaceuticals-nasdaq-nrxp-supports-executive-order-to-accelerate-psychedelic-drug-development/
NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality
April 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/20/3276858/0/en/nrx-pharmaceuticals-nasdaq-nrxp-welcomes-presidential-initiative-to-accelerate-approval-of-psychedelic-medications-to-treat-depression-ptsd-and-suicidality.html
NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications
April 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/15/3274303/0/en/nrx-pharmaceuticals-advances-robotic-enabled-transcranial-magnetic-stimulation-combined-with-neuroplastic-therapy-for-military-and-first-responder-applications.html
See More NRx Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NRx Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NRx Pharmaceuticals and other key companies, straight to your email.

About NRx Pharmaceuticals

NRx Pharmaceuticals (NASDAQ:NRXP) is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications. The company’s development programs are designed to address high-unmet-need patient populations, applying precision-medicine principles to optimize dosing regimens and patient selection. By building on decades of prior clinical experience with these molecules, NRx aims to reduce development timelines and costs relative to novel drug discovery.

Headquartered in New York, NRx Pharmaceuticals operates a lean corporate structure, with R&D activities supported by a network of external partners and contract research organizations. The company is led by a management team with deep expertise in pharmaceutical development, regulatory affairs and commercial strategy, drawing on experience at major biotech and global healthcare companies. Through strategic collaborations and disciplined capital allocation, NRx seeks to advance its product candidates efficiently toward regulatory milestones and, ultimately, market approval.

View NRx Pharmaceuticals Profile
Earnings Tools